- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Oxurion NV H1 Loss Decreases | 1 | RTTNews | ||
| Mi | OXURION: Oxurion Publishes First Half 2026 Results | 347 | Actusnews Wire | Leuven, BELGIUM - September 30, 2026 - 08:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, published today its financial and business update for the six-month... ► Artikel lesen | |
| Mi | OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC, The Goldman Sachs Group, Inc and Goldman Sachs International | 326 | Actusnews Wire | Leuven, BELGIUM - September 30, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1... ► Artikel lesen | |
| Mi | OXURION: Oxurion enters into exclusive negotiations to acquire the business and assets of Eclevar, a MedTech-focused CRO | 535 | Actusnews Wire | Leuven, BELGIUM - September 30, 2026 - 08:00 AM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that it has entered into exclusive negotiations to... ► Artikel lesen | |
| 23.09. | OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | 350 | Actusnews Wire | Atlas Special Opportunities, LLC has converted 3 convertible bonds in Oxurion resulting in a EUR 75,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital... ► Artikel lesen | |
| 10.09. | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 312 | Actusnews Wire | Leuven, BELGIUM - August 28, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it... ► Artikel lesen | |
| 21.07. | OXURION: Oxurion expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV | 458 | Actusnews Wire | Leuven, BELGIUM - July 21, 2026 - 8:00 am CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announced that its subsidiary Axiodis CRO has entered into... ► Artikel lesen | |
| OXURION Aktie jetzt für 0€ handeln | |||||
| 14.07. | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 436 | Actusnews Wire | Leuven, BELGIUM - July 14, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it... ► Artikel lesen | |
| 08.07. | OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | 555 | Actusnews Wire | Atlas Special Opportunities, LLC has converted 3 convertible bonds in Oxurion resulting in a EUR 75,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital... ► Artikel lesen | |
| 06.07. | OXURION: Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module | 557 | Actusnews Wire | Leuven, BELGIUM - July 6th, 2026 - 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announced the commercial launch of the Exagis electronic... ► Artikel lesen | |
| 26.06. | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 448 | Actusnews Wire | Leuven, BELGIUM - June 26, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it... ► Artikel lesen | |
| 19.06. | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 498 | Actusnews Wire | Leuven, BELGIUM - June 18, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it... ► Artikel lesen | |
| 15.06. | OXURION: Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform | 586 | Actusnews Wire | Leuven, BELGIUM - June 8, 2026 - 19:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announces that Pierre Fabre Laboratories is utilizing Exagis... ► Artikel lesen | |
| 10.06. | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 447 | Actusnews Wire | Leuven, BELGIUM - June 10, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it... ► Artikel lesen | |
| 08.06. | OXURION: Oxurion launches a software-driven growth strategy with Exagis | 835 | Actusnews Wire | Key Highlights
Under Oxurion's ownership, Exagis has evolved from an internal eCRF solution into a broader Clinical Data Management System (CDMS) serving external customers
Exagis has already... ► Artikel lesen | |
| 03.06. | OXURION: Oxurion Announces Results on the Annual Shareholders' Meeting of 1 June 2026 | 497 | Actusnews Wire | Leuven, BELGIUM - June 3, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, held its annual shareholders' meeting on June 1, 2026. The shareholders... ► Artikel lesen | |
| 02.06. | OXURION: Oxurion expands its capabilities to address the growing demand for GLP-1 and peptide clinical research services | 544 | Actusnews Wire | Leuven, BELGIUM - June 2, 2026 - 18:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announced the launch of a dedicated service offering focused... ► Artikel lesen | |
| 02.06. | OXURION: Oxurion - Termination of discussions for the French CRO project (LOI dated 13/10/25) and prioritization of the international target (LOI dated 19/03/26) | 448 | Actusnews Wire | Leuven, BELGIUM - June 1st, 2026 - 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today announces the termination of discussions regarding the... ► Artikel lesen | |
| 29.05. | OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC | 459 | Actusnews Wire | Leuven, BELGIUM - May 29, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has... ► Artikel lesen | |
| 27.05. | OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | 509 | Actusnews Wire | Atlas Special Opportunities, LLC has converted 3 convertible bonds in Oxurion resulting in a EUR 75,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| ROCHE | 371,74 | -0,04 % | Roche will schneller forschen | BASEL (dpa-AFX) - Roche hat sich für die kommenden Jahre ehrgeizige Ziele gesetzt: Der Pharmakonzern will bis 2030 insgesamt 20 neue, besonders wirkungsvolle Medikamente hervorbringen und zugleich... ► Artikel lesen | |
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Biosimilars: Stada: Pembrolizumab aus China | ||
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen |
Das Unternehmen OXURION NV kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OXURION NV finden Sie auf Wallstreet Online.